Fragile X syndrome is a leading genetic cause of autism. People who have either condition often share certain traits, such as difficulties in social situations.

The U.S. Drug Enforcement Agency has made it legal for doctors to prescribe an epilepsy drug derived from marijuana. But all other compounds derived from marijuana remain under tight restrictions.

The active ingredient in the drug popularly known as ecstasy eases social anxiety in people with autism.

Responding to serious concerns about its policy defining certain kinds of research as ‘clinical trials,’ the U.S. National Institutes of Health has postponed enforcing parts of the policy until September 2019.

The United States has approved a compound derived from marijuana as a treatment for certain types of epilepsy. The ruling may spell good news for autism research.

In May, the U.S. Food and Drug Administration guaranteed an experimental autism drug a speedy review for approval, but some scientists are skeptical of the drug’s potential.

A huge new research collaboration may jump-start the race to develop therapies for autism.

Many clinics offer neurofeedback as a therapy for autism, despite little scientific support for the technique.